Spectral domain optical coherence tomography documented rapid resolution of pseudophakic cystoid macular edema with topical difluprednate

• Published in: Clinical ophthalmology (Auckland, N.Z.) Vol. 6; no. default; pp. 155 - 158
• Main Authors: Chalam, Kv, Khetpal, Vijay, Patel, Chirag J
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2012; Taylor & Francis Ltd; Dove Press; Dove Medical Press
• Subjects: Care and treatment; Case Report; Cataracts; cystoid macular edema; difluprednate; Dropsy; Edema; Eye; Eye diseases; Eye surgery; Fluorescein; Health risk assessment; Ophthalmology; pseudophakic; spectral domain optical coherence tomography; Surgery; Tomography; difluprednate; cystoid macular edema; spectral domain optical coherence tomography; pseudophakic
• ISSN: 1177-5483; 1177-5467; 1177-5483
• DOI: 10.2147/OPTH.S28151

Pseudophakic cystoid macular edema is a common cause of poor vision after cataract surgery, and topical corticosteroids and nonsteroidal anti-inflammatory drugs are used for its treatment. We investigated the effectiveness of difluprednate (Durezol(®), recently approved by the US Food and Drug Administration) in the treatment of cystoid macular edema, assisted with spectral domain optical coherence tomography (SD-OCT). A 63-year-old African-American woman presented 6 weeks after uneventful cataract surgery in her left eye with decreased vision and associated distortion of the central visual field. Fluorescein angiogram and SD-OCT confirmed pseudophakic cystoid macular edema. Difluprednate was topically administered twice daily and monitored with serial imaging. Resolution was noted after 1 month of topical therapy, with improvement in visual acuity and resolution of distortion. Difluprednate is an effective treatment for patients with severe pseudophakic cystoid macular edema. SD-OCT allows the physician to monitor resolution of the macular edema easily.